A phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5438 Given Orally, in 2 dosing schedules (4 x daily dosing for 14 consecutive days in a 21-day period or 4 x daily dosing for 7 consecutive days in a 21 day period) in Patients with Advanced Solid Malignancies.

Study identifier:D0110C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5438 Given Orally, in 2 dosing schedules (4 x daily dosing for 14 consecutive days in a 21-day period or 4 x daily dosing for 7 consecutive days in a 21 day period) in Patients with Advanced Solid Malignancies.

Medical condition

solid tumour

Phase

Phase 1

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Oct 2004

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

Trial Results Summaries
Available here